Bio-Techne's Ella Platform Receives CE-IVD Marking, Expanding Rapid Immunoassay Access in European Clinical Laboratories
Key Insights
Bio-Techne Corporation (search) announced that its Ella benchtop immunoassay platform has received CE-IVD marking and is now available for sale in the European Union.
The compact, cartridge-based system delivers accurate biomarker results in under 90 minutes with minimal hands-on time, reducing operator variability in clinical settings.
The platform is compatible with Simple Plex (search) assays covering more than 390 analytes across neuroscience, immunology, oncology, and cell and gene therapy applications.
Bio-Techne Corporation (search) announced that its Ella benchtop immunoassay platform has received CE-IVD marking and is now available for sale in the European Union. This regulatory milestone enables European clinical laboratories to access the platform's rapid, cartridge-based immunoassay capabilities for diagnostic applications and clinical research.
Platform Capabilities and Performance
Ella is a compact, cartridge-based immunoassay system that delivers accurate biomarker results in under 90 minutes with minimal hands-on time. By simplifying the manual steps of traditional immunoassays, the platform reduces operator variability and provides high-quality, reproducible data suitable for both translational research and clinical applications.
The system is compatible with Simple Plex (search) assays, which remain for research use only, and are powered by R&D Systems (search) antibodies and proteins. The Simple Plex portfolio encompasses more than 390 analytes across neuroscience, immunology, oncology, and cell and gene therapy, enabling researchers to maintain consistency and data quality while working efficiently across diverse applications.
Clinical Applications and Market Access
With CE-IVD marking now in place, hospitals, clinical laboratories, and other European organizations may use Ella as a validated platform for in-house test development, clinical trials, and other translational activities. Diagnostic assay developers may also develop clinical applications on the Ella CE-IVD validated platform.
"Ella's CE-IVD certification marks a significant step forward in advancing precision diagnostics," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "It reflects our commitment to providing innovative tools that enhance clinical decision-making and improve patient outcomes."
Regulatory Significance
CE-IVD marking signifies that a product complies with the European Union's In Vitro Diagnostic Regulation (IVDR, Regulation (EU)2017/746), confirming its safety, performance, and reliability for clinical use. The certification enhances confidence in Ella's performance and supports Bio-Techne's long-term goal to advance precision medicine by providing dependable, standardized solutions for biomarker detection.
Company Background
Bio-Techne Corporation (search) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide.